Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan

World Journal of Gastroenterology

Volumn 21, Issue 37, 2015, Pages 10669-10674

  Wu, I Ting ^a   Chuah, Seng Kee ^a   Lee, Chen Hsiang ^a   Liang, Chih Ming ^a   Lu, Lung Sheng ^a   Kuo, Yuan Hung ^a   Yen, Yi Hao ^a   Hu, Ming Luen ^a   Chou, Yeh Pin ^a   Yang, Shih Cheng ^a   Kuo, Chung Mou ^a   Kuo, Chung Huang ^a   Chien, Chun Chih ^b   Chiang, Yu Shao ^a   Chiou, Shue Shian ^a   Hu, Tsung Hui ^a   Tai, Wei Chen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antibiotic resistance; Failed first line therapy; Five year sequential changes; Helicobacter pylori; Southern Taiwan

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; ANTIINFECTIVE AGENT;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; EPSILOMETER TEST; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STOMACH BIOPSY; TAIWAN; TREATMENT FAILURE; BIOPSY; DRUG EFFECTS; HELICOBACTER INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RETROSPECTIVE STUDY; TIME FACTOR;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BIOPSY; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MICROBIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; TAIWAN; TETRACYCLINE; TIME FACTORS;

EID: 84942765248     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i37.10669     Document Type: Article

References (39)

1. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007;117:60-69 [PMID: 17200707 DOI: 10.1172/JCI30111]
2. Teh BH, Lin JT, Pan WH, Lin SH, Wang LY, Lee TK, Chen CJ. Seroprevalence and associated risk factors of Helicobacter pylori infection in Taiwan. Anticancer Res 1994;14:1389-1392 [PMID: 8067711]
3. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
4. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009;24:1230-1235 [PMID: 19476562 DOI: 10.1111/j.1440-1746.2009.05829.x]
5. Hu CT, Wu CC, Lin CY, Cheng CC, Su SC, Tseng YH, Lin NT. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol 2007;22:720-723 [PMID: 17444862 DOI: 10.1111/j.1440-1746.2006.04743.x]
6. Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacinamoxicillin/clavulanate-rabeprazole versus a standard sevenday triple therapy for eradication of Helicobacter pylori infection. Biomed Res Int 2014;2014:158520 [PMID: 24995271 DOI: 10.1155/2014/158520]
7. Tai WC, Liang CM, Lee CH, Chiu CH, Hu ML, Lu LS, Kuo YH, Kuo CM, Yen YH, Kuo CH, Chiou SS, Wu KL, Chiu YC, Hu TH, Chuah SK. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication. Biomed Res Int 2015;2015:623732 [PMID: 26090428 DOI: 10.1155/2015/623732]
8. Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, Tsay FW, Wu CJ, Lo CC, Tseng HH, Yamaoka Y, Chen JL, Lo GH. A prospective randomized trial of esomeprazole-versus pantoprazolebased triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005;100:2387-2392 [PMID: 16279889 DOI: 10.1111/j.1572-0241.2005.00264.x]
9. Chuah SK, Tai WC, Lee CH, Liang CM, Hu TH. Quinolonecontaining therapies in the eradication of Helicobacter pylori. Biomed Res Int 2014;2014:151543 [PMID: 25243116 DOI: 10.1155/2014/151543]
10. Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O, Kim JG, Osato MS, Graham DY, Yamaoka Y. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol 2002;97:2231-2238 [PMID: 12358238 DOI: 10.1111/j.1572-0241.2002.05977.x]
11. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment - a pilot study. Helicobacter 2012;17:374-381 [PMID: 22967121 DOI: 10.1111/j.1523-5378.2012.00960.x]
12. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol 2013;19:8168-8180 [PMID: 24363506 DOI: 10.3748/wjg.v19.i45.8168]
13. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013;88:33-45 [PMID: 23880479 DOI: 10.1159/000350719]
14. Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015;13:895-905.e5 [PMID: 25460556 DOI: 10.1016/j.cgh.2014.10.036]
15. Tsugawa H, Suzuki H, Satoh K, Hirata K, Matsuzaki J, Saito Y, Suematsu M, Hibi T. Two amino acids mutation of ferric uptake regulator determines Helicobacter pylori resistance to metronidazole. Antioxid Redox Signal 2011;14:15-23 [PMID: 20518707 DOI: 10.1089/ars.2010.3146]
16. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]
17. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-567 [PMID: 12650788]
18. Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M, Santarelli L, Zocco MA, Ojetti V, Carloni E, Cammarota G, Gasbarrini G, Gasbarrini A. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-633 [PMID: 12969089 DOI: 10.1046/j.1365-2036.2003.01676.x]
19. Gerrits MM, van der Wouden EJ, Bax DA, van Zwet AA, van Vliet AH, de Jong A, Kusters JG, Thijs JC, Kuipers EJ. Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori. J Med Microbiol 2004;53:1123-1128 [PMID: 15496391]
20. Moon JY, Kim GH, You HS, Lee BE, Ryu DY, Cheong JH, Jung JI, Jeong JH, Song CS, Song GA. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver 2013;7:406-410 [PMID: 23898379 DOI: 10.5009/gnl.2013.7.4.406]
21. Goh KL, Navaratnam P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter 2011;16:241-245 [PMID: 21585611 DOI: 10.1111/j.1523-5378.2011.00841.x]
22. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013;18:206-214 [PMID: 23241101 DOI: 10.1111/hel.12031]
23. Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014;20:1517-1528 [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517]
24. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol 2009;58:930-935 [PMID: 19502370 DOI: 10.1099/jmm.0.009993-0]
25. Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, Liang CM, Lu LS, Chiu CH, Wu KL, Chiu YC, Hu TH, Chuah SK. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One 2014;9:e105822 [PMID: 25141137]
26. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009;14:61-65 [PMID: 19191898]
27. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori retreatment: role of bacterial resistance. Dig Liver Dis 2007;39:1001-1005 [PMID: 17889627 DOI: 10.1016/j.dld.2007.06.016]
28. Carothers JJ, Bruce MG, Hennessy TW, Bensler M, Morris JM, Reasonover AL, Hurlburt DA, Parkinson AJ, Coleman JM, McMahon BJ. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007;44:e5-e8 [PMID: 17173210 DOI: 10.1086/510074]
29. Jeon CY, Calver AD, Victor TC, Warren RM, Shin SS, Murray MB. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis 2011;15:77-83 [PMID: 21276301]
30. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, Smith T, Hooper N, Maruri F, Warkentin J, Mitchel E, Sterling TR. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365-370 [PMID: 19483111 DOI: 10.1164/rccm.200901-0146OC]
31. Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes 2013;4:541-548 [PMID: 23929066 DOI: 10.4161/gmic.25930]
32. Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol 2014;20:5283-5293 [PMID: 24833858 DOI: 10.3748/wjg.v20. i18.5283]
33. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232-260; second page, table of contents [PMID: 11381101 DOI: 10.1128/MMBR.65.2.232-260.2001]
34. Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, Wu DC, Hu TH. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter 2012;17:216-223 [PMID: 22515360 DOI: 10.1111/j.1523-5378.2012.00937.x]
35. Wu DC, Hsu PI, Tseng HH, Tsay FW, Lai KH, Kuo CH, Wang SW, Chen A. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore) 2011;90:180-185 [PMID: 21512411 DOI: 10.1097/MD.0b013e31821c9d1c]
36. Sorice F, Ortona L, Pizzigallo E. Further aspects of combination antibiotic therapy. Critical review and personal case studies. Minerva Med 1975;66:2805-2822 [PMID: 1161172]
37. Pavicić MJ, Namavar F, Verboom T, van Winkelhoff AJ, De Graaff J. In vitro susceptibility of Helicobacter pylori to several antimicrobial combinations. Antimicrob Agents Chemother 1993;37:1184-1186 [PMID: 8517712 DOI: 10.1128/AAC.37.5.1184]
38. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322 [PMID: 17428887 DOI: 10.1128/CMR.00033-06]
39. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-278 [PMID: 17669098 DOI: 10.1111/j.1523-5378.2007.00518.x]